Q2 2026 delivered strong revenue and net income growth, driven by record net bookings, a surge in oncology awards, and improved business conditions. Guidance for 2026 was raised, with robust cash flow and significant share repurchases supporting capital allocation.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.